Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable XXXX .

@entity1 @entity137 @entity55 @entity5 @entity2910 @entity1149 @entity1909 @entity1349
PURPOSE: We report long-term disease control, survival, and @entity137 for @entity1 with locally advanced @entity1149 prospectively treated with concurrent proton therapy and chemotherapy on a nonrandomized case-only observational study. METHODS: All @entity1 received passive-scatter proton therapy, planned with 4D-CT-based simulation; all received proton therapy concurrent with weekly chemotherapy. Endpoints were local and distant control, disease-free survival (DFS), and @entity1349 ( @entity1349 ). RESULTS: The 134 @entity1 (21 stage II, 113 stage III; median age 69years) had a median gross @entity5 volume (GTV) of 70cm(3) (range, 5-753cm(3)); 77 @entity1 (57%) received 74Gy(RBE), and 57 (42%) received 60-72Gy(RBE) (range, 60-74.1Gy(RBE)). At a median follow-up time of 4.7years, median @entity1349 times were 40.4months (stage II) and 30.4months (stage III). Five-year DFS rates were 17.3% (stage II) and 18.0% (stage III). @entity1349 , DFS, and local and distant control rates at 5years did not differ by disease stage. Age and GTV were related to @entity1349 and DFS. @entity137 was tolerable, with 1 grade 4 @entity2910 and 16 grade 3 events (2 @entity55 , 6 @entity2910 , 8 @entity1909 ). CONCLUSION: This report of outcomes after proton therapy for 134 @entity1 indicated that this regimen produced excellent @entity1349 with tolerable @entity137 .
